logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

EndoStim ($STIM) is a medical device company focused on the development and commercialization of a novel neurostimulation system for the treatment of severe gastroesophageal reflux disease, or GERD. It is based in St. Louis, MO. Four other companies are scheduled for the week of Oct. 20, 2014.  The full IPO…
Read more...
Targeting kidney failure, Proteon Therapeutics ($PRTO) initiated the first of two Phase 3 trials for PRT-201 in radiocephalic AVFs, PRTO’s initial indication, in the third quarter of 2014 and expect to initiate the second Phase 3 trial in the first half of 2015. It is headquartered in Waltham, MA. Four other…
Read more...
Every business day, Edison Investment Research Analyst Pooya Hemami scours the global markets for life science companies with upside flowing through their product pipelines. In this interview with The Life Sciences Report, Dr. Hemami tells us where to look for biotech bargains, including a few top-fliers and a handful of…
Read more...
Griffin Securities has assembled a biotech portfolio weighted toward companies pursuing high-science therapeutic approaches. However, as analyst Keith Markey explains, through a combination of pipeline diversification, positive clinical data and low-cost research and development strategies, many companies are able to mitigate the risk inherent in their technologies. In this interview…
Read more...
Xenon Pharmaceuticals ($XENE) is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. It is headquartered in Burnaby, British Columbia, Canada. Six other companies are scheduled for the week of Oct. 13, 2014. The full IPO calendar is available at IPOpremium. The manager and…
Read more...
Virobay ($VBAY) is a clinical-stage pharmaceutical company utilizing its cysteine cathepsin platform for the development and commercialization of novel drugs. It is headquartered in Menlo Park, CA. Six other companies are scheduled for the week of Oct. 13, 2014. The full IPO calendar is available at IPOpremium. The manager and…
Read more...
Ebola paranoia is spreading the country. At least, it’s spreading a lot faster than the actual Ebola virus, which is still limited to two total cases in the United States. Cable news stations are giving the story enough coverage to make one think the entire world is ending, though, so…
Read more...
NeuroSigma ($NSIG) scheduled a $50 million IPO with a market capitalization of $17 million at a price range midpoint of $14 for Thursday, Nov. 9, 2014 on Nasdaq. SEC filings Seven other companies are scheduled for the week of Oct. 6, 2014. The full IPO calendar is available at IPOpremium. NeuroSigma is a…
Read more...
It was a pretty brutal trading day on Wednesday after Arrowhead Research (ARWR) announced that its Hepatitis B treatment, ARC-520, had failed to return positive top-line results. The news hit the markets at 10:00 am EST, making for a rare instance where the bottom falls out from under a stock…
Read more...
Australia is a powerhouse for medical science innovations, and nobody understands that better than Scott Power of Morgans Financial Ltd. Power watched the weaker Australian firms go the way of the dodo bird during the downturn in the biotech sector earlier this year, leaving only the fittest for investors to…
Read more...
Dermira ($DERM) is a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients. It is based in Redwood City, CA. Ten other companies are scheduled for the week of Sept. 29, 2014.  The full IPO calendar is available at IPOpremium. Manager, Joint-managers: …
Read more...
EyeGate Pharmaceuticals ($EYEG) EYEG is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. It is based in Waltham, MA. Ten other companies are scheduled for the week of Sept. 29, 2014. The full IPO calendar…
Read more...
Page 1 of 46

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.